VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vir Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.21+0.25 (+2.51%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Vir Biotechnology, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant revenue | $638.00K | $810.00K | $2.04M | $2.82M | $4.61M | $6.56M | $10.49M | $16.58M | $21.23M | $35.61M | $46.69M | $67.12M | 0.2% | -86.2% |
| Other revenue | – | – | – | $4.26M | $5.65M | $5.01M | $55.33M | $55.21M | $54.11M | $54.28M | $2.23M | $1.66M | – | – |
| Collaboration revenue | – | – | – | $9.78M | $8.75M | $9.30M | $8.38M | $6.82M | $3.54M | -$10.30M | $37.27M | $50.02M | – | – |
| Profit-sharing amount | – | – | – | – | – | – | $9.08M | $7.40M | $2.46M | -$5.99M | $1.54M | $4.58M | – | – |
| Profit-sharing amount constrained | – | – | – | – | – | – | -$699.00K | -$700.00K | -$700.00K | -$6.08M | $0 | $24.80M | – | – |
| Profit-sharing amount previously constrained, released | – | – | – | – | – | – | $0 | $124.00K | $1.78M | $1.78M | $35.73M | – | – | – |
| License Revenue | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Vir Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.